Arch Therapeutics, Inc. (ARTH)

OTCMKTS: ARTH · Delayed Price · USD
1.835
0.00 (0.00%)
Feb 26, 2024, 10:29 AM EST - Market open
Market Cap 8.70M
Revenue (ttm) 115,331
Net Income (ttm) -7.98M
Shares Out 4.74M
EPS (ttm) -3.31
PE Ratio n/a
Forward PE 0.07
Dividend n/a
Ex-Dividend Date n/a
Volume 105
Open 1.835
Previous Close 1.835
Day's Range 1.835 - 1.835
52-Week Range 0.390 - 18.000
Beta 3.65
Analysts n/a
Price Target n/a
Earnings Date n/a

About ARTH

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol ARTH
Full Company Profile

Financial Performance

In 2023, ARTH's revenue was $75,724, an increase of 383.80% compared to the previous year's $15,652. Losses were -$6.98 million, 63.3% more than in 2022.

Financial Statements

News

Arch Therapeutics Provides Year End Operational Update

Fiscal year-end AC5 Advanced Wound System update includes Q4 record monthly order volumes, favorable reimbursement decisions and increases in paid claims.

3 months ago - GlobeNewsWire

Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today annou...

4 months ago - GlobeNewsWire

Arch Therapeutics Provides AC5® Commercialization Update

Orders and Paid Claims Increasing Since Rollout of Reimbursement Code Orders and Paid Claims Increasing Since Rollout of Reimbursement Code

5 months ago - GlobeNewsWire

Arch Therapeutics Completes Financing as Bridge to Uplisting

Common Stock Listing on National Exchange is Next Planned Significant Milestone Common Stock Listing on National Exchange is Next Planned Significant Milestone

6 months ago - GlobeNewsWire

Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)

SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement code SAWC Spring 2023 represents first clinical conference opportunity ...

10 months ago - GlobeNewsWire

Dedicated HCPCS Billing Code for Arch Therapeutics' AC5® Advanced Wound System Now In Effect

New code is expected to advance commercialization efforts in doctors' offices and other outpatient settings New code is expected to advance commercialization efforts in doctors' offices and other outp...

11 months ago - GlobeNewsWire

Arch Therapeutics' AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services

The new code represents a key milestone for the commercialization of AC5® Advanced Wound System in doctors' offices and other outpatient settings The new code represents a key milestone for the commer...

1 year ago - GlobeNewsWire

Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities

Dedicated representation in selected geographic locations to support new and recurring sales in government facilities Dedicated representation in selected geographic locations to support new and recur...

1 year ago - GlobeNewsWire

Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goals Wound care professionals across multiple specialties to support strategic alig...

1 year ago - GlobeNewsWire

Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange

FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical produ...

1 year ago - GlobeNewsWire

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics' AC5® Advanced Wound System

A dedicated code would represent a key milestone for commercialization of AC5 Advanced Wound System in doctors' offices and other outpatient settings A dedicated code would represent a key milestone f...

1 year ago - GlobeNewsWire

Key Opinion Leaders Presented Arch Therapeutics' AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall

Poster Presentation of AC5 Advanced Wound System received award for Highest Scoring Poster Abstract in its category Poster Presentation of AC5 Advanced Wound System received award for Highest Scoring ...

1 year ago - GlobeNewsWire

Arch Therapeutics' AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall

Awarded Highest Scoring Poster Abstract in Case Series / Study Category Awarded Highest Scoring Poster Abstract in Case Series / Study Category

1 year ago - GlobeNewsWire

Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

Significant Milestone in Commercialization Plan Expected to Drive Sales Momentum Significant Milestone in Commercialization Plan Expected to Drive Sales Momentum

1 year ago - GlobeNewsWire

Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)

Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic Products in Wound Healing Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic ...

1 year ago - GlobeNewsWire

Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange

Consistent with Long-Term Strategic Plan to Increase Capital Market Visibility and Enhance Access to Growth Capital Consistent with Long-Term Strategic Plan to Increase Capital Market Visibility and E...

1 year ago - GlobeNewsWire

Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System

Expected to Accelerate Sales Opportunities in Doctor's Office and Wound Clinics Expected to Accelerate Sales Opportunities in Doctor's Office and Wound Clinics

1 year ago - GlobeNewsWire

Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System

HCPCS Code May Support Product Differentiation and Enhance Existing Sales Opportunities Under New CMS 2022 Billing and Reimbursement Pathway for Synthetic Skin Substitutes HCPCS Code May Support Produ...

1 year ago - GlobeNewsWire

Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing

Uplisting is the Next Significant Step Uplisting is the Next Significant Step

1 year ago - GlobeNewsWire

Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarter Initial A4100 code being deployed and application for specific HCPCS pr...

1 year ago - GlobeNewsWire

Arch Therapeutics' Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring

World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound System World-renowned Wound Care Leaders, Terry Treadwell, MD, FA...

1 year ago - GlobeNewsWire

Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics' AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring

Additional data covered a variety of specialties, including vascular surgery, plastic surgery, general surgery, and podiatry, to further support clinical efficacy of AC5® Advanced Wound System in acut...

2 years ago - GlobeNewsWire

Arch Therapeutics' AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring

Additional case studies and key opinion leader discussion continues to support the broad potential of AC5® Advanced Wound System Additional case studies and key opinion leader discussion continues to ...

2 years ago - GlobeNewsWire

Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System

Strategic Alliance Positioned to Grow Sales Opportunities in Non-Government Hospital Channel Strategic Alliance Positioned to Grow Sales Opportunities in Non-Government Hospital Channel

2 years ago - GlobeNewsWire

Clinical Evaluation Finds Arch Therapeutics' AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities

AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplication AC5® Advanced Wound System demonstrated notable i...

2 years ago - GlobeNewsWire